Wells Fargo
NKTR icon

Wells Fargo’s Nektar Therapeutics NKTR Stock Holding History

Wells Fargo’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.5K Buy
327
+136
+71% +$7.74K ﹤0.01% 5713
2025
Q4 		$8.08K Sell
191
-57
-23% -$3.19K ﹤0.01% 5996
2025
Q3 		$14.1K Sell
248
-269
-52% -$8.9K ﹤0.01% 5878
2025
Q2 		$13.4K Sell
517
-7,150
-93% -$80.3K ﹤0.01% 5880
2025
Q1 		$78.2K Buy
7,667
+402
+6% +$5.25K ﹤0.01% 5224
2024
Q4 		$101K Buy
7,265
+1,521
+26% +$26.8K ﹤0.01% 5196
2024
Q3 		$112K Buy
5,744
+245
+4% +$4.67K ﹤0.01% 4949
2024
Q2 		$102K Buy
5,499
+5,157
+1,508% +$109K ﹤0.01% 4930
2024
Q1 		$4.8K Buy
342
+1
+0.3% +$10 ﹤0.01% 5899
2023
Q4 		$2.88K Sell
341
-4
-1% -$30 ﹤0.01% 6036
2023
Q3 		$3.08K Sell
345
-234
-40% -$2.25K ﹤0.01% 6035
2023
Q2 		$4.99K Sell
579
-3,977
-87% -$42.4K ﹤0.01% 6081
2023
Q1 		$48K Buy
4,556
+3,646
+401% +$110K ﹤0.01% 5178
2022
Q4 		$30.9K Sell
910
-551
-38% -$26.7K ﹤0.01% 5080
2022
Q3 		$70K Sell
1,461
-16
-1% -$952 ﹤0.01% 4800
2022
Q2 		$84K Sell
1,477
-5,814
-80% -$367K ﹤0.01% 4740
2022
Q1 		$590K Sell
7,291
-370
-5% -$54.8K ﹤0.01% 4297
2021
Q4 		$1.55M Sell
7,661
-3,185
-29% -$691K ﹤0.01% 3742
2021
Q3 		$2.92M Sell
10,846
-1,408
-11% -$339K ﹤0.01% 3350
2021
Q2 		$3.15M Sell
12,254
-516
-4% -$143K ﹤0.01% 3282
2021
Q1 		$3.83M Sell
12,770
-4,131
-24% -$1.29M ﹤0.01% 3096
2020
Q4 		$4.31M Buy
16,901
+5,401
+47% +$1.4M ﹤0.01% 2890
2020
Q3 		$2.86M Sell
11,500
-5,993
-34% -$1.89M ﹤0.01% 3026
2020
Q2 		$6.08M Sell
17,493
-349
-2% -$109K ﹤0.01% 2285
2020
Q1 		$4.78M Buy
17,842
+553
+3% +$171K ﹤0.01% 2260
2019
Q4 		$5.6M Sell
17,289
-8,800
-34% -$2.55M ﹤0.01% 2460
2019
Q3 		$7.13M Buy
26,089
+3,515
+16% +$1.29M ﹤0.01% 2216
2019
Q2 		$12M Sell
22,574
-8,187
-27% -$4.11M ﹤0.01% 1823
2019
Q1 		$15.5M Buy
30,761
+8,737
+40% +$5.18M ﹤0.01% 1631
2018
Q4 		$10.9M Sell
22,024
-5,585
-20% -$3.37M ﹤0.01% 1797
2018
Q3 		$25.2M Buy
27,609
+15,587
+130% +$13.3M 0.01% 1357
2018
Q2 		$8.8M Sell
12,022
-2,479
-17% -$2.86M ﹤0.01% 2177
2018
Q1 		$23.1M Buy
14,501
+3,799
+35% +$4.89M 0.01% 1368
2017
Q4 		$9.59M Sell
10,702
-3,669
-26% -$2.17M ﹤0.01% 2035
2017
Q3 		$5.17M Buy
14,371
+680
+5% +$213K ﹤0.01% 2495
2017
Q2 		$4.01M Sell
13,691
-130
-0.9% -$37.6K ﹤0.01% 2611
2017
Q1 		$4.87M Buy
13,821
+946
+7% +$213K ﹤0.01% 2452
2016
Q4 		$2.37M Buy
12,875
+5,187
+67% +$1.05M ﹤0.01% 3026
2016
Q3 		$1.98M Buy
7,688
+440
+6% +$113K ﹤0.01% 2977
2016
Q2 		$1.55M Sell
7,248
-1,146
-14% -$256K ﹤0.01% 3162
2016
Q1 		$1.73M Buy
8,394
+1,069
+15% +$205K ﹤0.01% 3030
2015
Q4 		$1.85M Buy
7,325
+728
+11% +$150K ﹤0.01% 3040
2015
Q3 		$1.08M Sell
6,597
-1,210
-15% -$214K ﹤0.01% 3437
2015
Q2 		$1.47M Buy
7,807
+2,799
+56% +$482K ﹤0.01% 3306
2015
Q1 		$826K Sell
5,008
-613
-11% -$126K ﹤0.01% 3645
2014
Q4 		$1.31M Buy
5,621
+2,861
+104% +$612K ﹤0.01% 3324
2014
Q3 		$500K Buy
2,760
+1,869
+210% +$358K ﹤0.01% 3898
2014
Q2 		$172K Sell
891
-142
-14% -$25.1K ﹤0.01% 4437
2014
Q1 		$188K Buy
1,033
+857
+487% +$170K ﹤0.01% 4362
2013
Q4 		$30K Buy
176
+33
+23% +$5.32K ﹤0.01% 4887
2013
Q3 		$22K Sell
143
-1,473
-91% -$272K ﹤0.01% 4924
2013
Q2 		$280K Buy
+1,616
New +$248K ﹤0.01% 3980

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wells Fargo's NKTR Position: Q1 2026 in Review

Wells Fargo increased its Nektar Therapeutics (NKTR) stake by 71% in Q1 2026, buying an estimated $7.74K and bringing the position to 327 shares worth $23.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5713.

Wells Fargo first reported a position in NKTR in Q2 2013 and has held it in 52 quarters since. The position peaked at $25.2M in Q3 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Wells Fargo held 327 shares of Nektar Therapeutics worth $23.5K as of Q1 2026.
  • Wells Fargo bought 136 Nektar Therapeutics shares in Q1 2026, an estimated $7.74K.
  • Nektar Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5713 holding.
  • Wells Fargo first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's Nektar Therapeutics position peaked at $25.2M in Q3 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.